FASEB Conf. Proteases in Hemostasis and Vascular Biology

描述(由申请人提供)： 美国实验生物学学会联合会(FASE B)将于2005年7月9-14日在佛蒙特州萨克斯顿河举办“止血和血管生物学中的蛋白酶”会议，现申请部分资金。这次会议是1992年开始的一系列会议中的第七次。该计划代表着从最初专注于凝血酶向更广泛的蛋白酶及其在止血和血管生物学中的作用的领域的演变。鉴于最近的事态发展进一步加深了我们对心血管疾病的基础的了解，人们对这一领域的兴趣是巨大的。该会议已在该领域站稳脚跟，并享有国际声誉，因为它是一个以平衡、非正式和高度互动的方式讨论基础科学、生物技术和医学问题的论坛。血栓形成和止血领域的一些最引人注目的成就首先在这次会议上浮出水面，或者是这次会议促进了产业界和学术界之间的合作互动的结果。经确认的发言者名单包括初级调查人员以及该领域的知名领导人。与以往的会议一样，我们将努力促进妇女和少数群体的参与，并将为初级教员、学生、博士后研究员和残疾人提供奖学金，并在该计划中包括9个从与会者提交的摘要中挑选出来的年轻研究人员的空缺。该计划分为九个部分：1.蛋白水解酶和凝血；2.全身效应；3.蛋白水解酶和血小板；4.热点；5.新分子和新方法；6.ADAMTS13和相关的蛋白水解酶；7.组织因子、血小板和凝血；8.止血调节；9.蛋白水解酶受体。主旨演讲将由Katherine High博士发表，主题是止血障碍的基因疗法。

DESCRIPTION (provided by applicant): This is an application for partial funding of a conference on "Proteases in Hemostasis and Vascular Biology" sponsored by the Federation of American Societies of Experimental Biology (FASEB) to be held in Saxton's River, VT, from July 9-14, 2005. The conference is the 7th in a series started in 1992. The program represents an evolution from the original focus on thrombin into the broader arena of proteases and their role in hemostasis and vascular biology. Interest in this area is enormous in view of recent developments that have furthered our understanding of the underpinnings of cardiovascular disease. The conference has established itself in the field and enjoys an international reputation for being a forum where basic science, biotechnology and medical issues are discussed in a balanced, informal and highly interactive manner. Some of the most spectacular achievements in the area of thrombosis and hemostasis have first surfaced at this conference, or have resulted from collaborative interactions between industry and academia fostered by this conference. The roster of confirmed speakers includes junior investigators as well as well known leaders in the field. As in past conferences, we will endeavor to promote participation of women and minorities and will provide fellowships for junior faculty, students, postdoctoral fellows and people with disabilities, as well as including in the program 9 openings for younger investigators selected from abstracts submitted by attendees. The program is organized in nine sessions: 1. Proteases and coagulation; 2. Systemic effects; 3. Proteases and platelets; 4. Hot stuff; 5. Novel molecules and novel approaches; 6. ADAMTS13 and related proteases; 7. Tissue factor, platelets and coagulation; 8. Regulators of hemostasis; 9. Protease receptors. The keynote lecture will be on gene therapy for disorders of hemostasis delivered by Dr. Katherine High.